Patents by Inventor Robert I. Lehrer
Robert I. Lehrer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8716246Abstract: Azuvirin peptides are small peptide agents useful in delivering functional moieties, such as sensitizers, chemotherapeutic agents and the like to cancer cells expressing ephrin receptors. The peptides are also useful for administration to a patient suffering from a viral infection, or to an individual facing exposure to a viral infection, especially one caused by the Human Immunodeficiency Virus (HIV-1).Type: GrantFiled: January 3, 2012Date of Patent: May 6, 2014Assignee: The Regents of the University of CaliforniaInventors: Piotr P. Ruchala, Robert I. Lehrer
-
Publication number: 20130029903Abstract: Azuvirin peptides are small peptide agents useful in delivering functional moieties, such as sensitizers, chemotherapeutic agents and the like to cancer cells expressing ephrin receptors. The peptides are also useful for administration to a patient suffering from a viral infection, or to an individual facing exposure to a viral infection, especially one caused by the HIV-1 retrovirus.Type: ApplicationFiled: January 3, 2012Publication date: January 31, 2013Inventors: Piotr P. Ruchala, Robert I. Lehrer
-
Patent number: 7718610Abstract: Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.Type: GrantFiled: January 1, 2008Date of Patent: May 18, 2010Assignee: The Regents of the University of CaliforniaInventors: Robert I. Lehrer, Alan J. Waring, Alexander M. Cole, Teresa B. Hong
-
Publication number: 20090264344Abstract: Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.Type: ApplicationFiled: January 1, 2008Publication date: October 22, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: ROBERT I. LEHRER, ALAN J. WARING, ALEXANDER M. COLE, TERESA B. HONG
-
Patent number: 7314858Abstract: Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.Type: GrantFiled: November 5, 2004Date of Patent: January 1, 2008Assignee: The Regents of the University of CaliforniaInventors: Robert I. Lehrer, Alan J. Waring, Alexander M. Cole, Teresa B. Hong
-
Publication number: 20040152638Abstract: Peptide-based compounds containing four invariant cysteine residues which have been optionally oxidized to contain two intramolecular disulfide bonds, or modified forms where the cysteines are replaced are useful as preservatives and in preventing, treating, or ameliorating viral or microbial infection in animals and plants, and in inactivating endotoxin.Type: ApplicationFiled: July 24, 2003Publication date: August 5, 2004Applicant: The Regents of the University of CaliforniaInventors: Robert I. Lehrer, Sylvia S.L. Harwig, Vladimir N. Kokryakov
-
Patent number: 6713078Abstract: Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.Type: GrantFiled: May 6, 2002Date of Patent: March 30, 2004Assignee: The Regents of the University of CaliforniaInventors: Robert I. Lehrer, Alan J. Waring, Alexander M. Cole, Teresa B. Hong
-
Patent number: 6653442Abstract: Peptide-based compounds containing four invariant cysteine residues which have been optionally oxidized to contain two intramolecular disulfide bonds, or modified forms where the cysteines are replaced are useful as preservatives and in preventing, treating, or ameliorating viral or microbial infection in animals and plants, and in inactivating endotoxin.Type: GrantFiled: August 30, 1999Date of Patent: November 25, 2003Assignee: IntraBiotics Pharmaceuticals, Inc.Inventors: Conway C. Chang, Chee L. Gu, Jie Chen, Deborah A. Steinberg, Robert I. Lehrer, Sylvia S. L. Harwig, Vladimir N. Kokryakov
-
Publication number: 20030144184Abstract: Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing exposure to a bacterial and/or viral infection, especially one caused by the HIV-1 retrovirus or other sexually-transmitted pathogens.Type: ApplicationFiled: May 6, 2002Publication date: July 31, 2003Inventors: Robert I. Lehrer, Alan J. Waring, Alexander M. Cole, Teresa B. Hong
-
Publication number: 20030100483Abstract: Peptide-based compounds containing four invariant cysteine residues which have been optionally oxidized to contain two intramolecular disulfide bonds, or modified forms where the cysteines are replaced are useful as preservatives and in preventing, treating, or ameliorating viral or microbial infection in animals and plants, and in inactivating endotoxin.Type: ApplicationFiled: March 30, 2000Publication date: May 29, 2003Inventors: Robert I. Lehrer, Sylvia S.L. Harwig, Vladimir N. Kokryakov
-
Patent number: 6492328Abstract: Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.Type: GrantFiled: April 19, 2001Date of Patent: December 10, 2002Assignees: The University of Iowa Research Foundation, The Regents of the University of CaliforniaInventors: Robert I. Lehrer, Alan J. Waring, Brian F. Tack
-
Publication number: 20020147301Abstract: The present invention provides a new class of broad-spectrum antimicrobial peptides effective against a wide variety of microbes, including bacteria, viruses, retroviruses, fungi, yeast and protozoa.Type: ApplicationFiled: May 24, 2001Publication date: October 10, 2002Applicant: IntraBiotics Pharmaceuticals, Inc.Inventors: Robert I. Lehrer, Sylvia S.L. Harwig, Conway C. Chang, Chee L. Gu
-
Publication number: 20020082195Abstract: Novispirin peptides are antimicrobial agents with potent activity against Gram-negative bacteria. The peptides are nonhemolytic, exhibit reduced in vitro cytotoxicity relative to other antimicrobial peptides, and were well-tolerated in vivo after intravenous injection. Novispirins also bind lipopolysaccharide (LPS), a property that may mitigate symptoms associated with Gram-negative bacterial infection. A pharmaceutical composition comprising novispirin as an active agent is administered to a patient suffering from or predisposed to a microbial infection, particularly Gram-negative bacterial infections.Type: ApplicationFiled: April 19, 2001Publication date: June 27, 2002Inventors: Robert I. Lehrer, Alan J. Waring, Brian F. Tack
-
Publication number: 20020034739Abstract: Peptides that are characteristic of tumors of the steroid regulated organs are disclosed. The peptides are useful for the production of antibodies that may in turn be used to detect metastases of these tumors. The antibodies may also be used for purifying the peptides.Type: ApplicationFiled: July 7, 1998Publication date: March 21, 2002Inventors: ROBERT I. LEHRER, CHENGQUAN ZHAO, BENJAMIN J. GLASGOW
-
Patent number: 6307016Abstract: The present invention provides a new class of broad-spectrum antimicrobial peptides effective against a wide variety of microbes, including bacteria, viruses, retroviruses, fungi, yeast and protozoa.Type: GrantFiled: August 3, 1998Date of Patent: October 23, 2001Assignee: IntraBiotics Pharmaceuticals, Inc.Inventors: Robert I. Lehrer, Sylvia S. L. Harwig, Conway C. Chang, Chee L. Gu
-
Patent number: 6159936Abstract: Peptide-based compounds containing four invariant cysteine residues which have been optionally oxidized to contain two intramolecular disulfide bonds, or modified forms where the cysteines are replaced are useful as preservatives and in preventing, treating, or ameliorating viral or microbial infection in animals and plants, and in inactivating endotoxin. These compounds, in one embodiment, are of the formula:A.sub.1 --A.sub.2 --A.sub.3 --A.sub.4 --A.sub.5 --A.sub.6 --A.sub.7 --A.sub.8 --A.sub.9 --A.sub.10 --A.sub.11 --A.sub.12 --A.sub.13 --A.sub.14 --A.sub.15 --A.sub.16 --(A.sub.17 --A.sub.18) (1)and the N-terminal acylated and/or C-terminal amidated or esterified forms thereof, which is either in the optionally --SH stablizied linear or in a cystine-bridged formwherein each of A.sub.1 and A.sub.9 is independently a basic amino acid;each of A.sub.2 and A.sub.3 is independently a small amino acid;each of A.sub.5, A.sub.7, A.sub.12, A.sub.14 and A.sub.16 is independently a hydrophobic amino acid;A.sub.Type: GrantFiled: August 3, 1998Date of Patent: December 12, 2000Assignee: The Regents of the University of CaliforniaInventors: Robert I. Lehrer, Sylvia S. L. Harwig, Vladimir N. Kokryakov
-
Patent number: 6043220Abstract: The invention is directed to antimicrobial peptides related to naturally-occurring protegrin peptides, and methods of using the peptides in a variety of contexts, including the treatment or prevention of infections, and diseases related thereto.Type: GrantFiled: December 3, 1997Date of Patent: March 28, 2000Assignee: IntraBiotics Pharmaceuticals, Inc.Inventors: Conway C. Chang, Jie Chen, Robert I. Lehrer, Peggy A. Radel
-
Patent number: 6040293Abstract: Novel microbial peptides called clavanins are of the formula[X'.sub.1 X.sub.2 B'.sub.3 X.sub.4 X.sub.5 ]U.sub.6 B.sub.7 X.sub.8 X.sub.9 B.sub.10 B.sub.11 X.sub.12 U.sub.13 Z.sub.14 X.sub.15 X.sub.16 B*.sub.17 U.sub.18 X.sub.19 U.sub.20 B.sub.21 X.sub.22 X.sub.23 ( 1)(SEQ ID NO:1 )including the salts, esters, amides and acylated forms thereofwherein X is a hydrophobic amino acid residue or modified form thereof;X' is a small or a hydrophobic amino acid residue or a modified form thereof;B is a basic amino acid residue or modified form thereof;B' is basic or a polar/large amino acid residue or modified form thereof; andB* is a basic or a hydrophobic amino acid residue or a modified form thereof;U is a small amino acid residue or modified form thereof;Z is a polar/large amino acid residue or modified form thereof, and wherein 1-5 amino acids is deleted from the N-terminus.Type: GrantFiled: February 28, 1997Date of Patent: March 21, 2000Assignee: The Regents of the University of CaliforniaInventors: Robert I. Lehrer, Chengquan Zhao, In-Hee Lee
-
Patent number: 6010876Abstract: Novel microbial peptides called clavanins are of the formulaX'.sub.1 X.sub.2 B'.sub.3 X.sub.4 X.sub.5 U.sub.6 B.sub.7 X.sub.8 X.sub.9 B.sub.10 B.sub.11 X.sub.12 U.sub.13 Z.sub.14 X.sub.15 X.sub.16 B*.sub.17 U.sub.18 X.sub.19 U.sub.20 B.sub.21 X.sub.22 X.sub.23 ( 1)(SEQ ID NO: 1)including the salts, esters, amides and acylated forms thereofwherein X is a hydrophobic amino acid residue or modified form thereof;X' is a small or a hydrophobic amino acid residue or a modified form thereof;B is a basic amino acid residue or modified form thereof;B' is basic or a polar/large amino acid residue or modified form thereof; andB* is a basic or a hydrophobic amino acid residue or a modified form thereof;U is a small amino acid residue or modified form thereof;Z is a polar/large amino acid residue or modified form thereof.Type: GrantFiled: November 6, 1996Date of Patent: January 4, 2000Assignee: The Regents of the University of CaliforniaInventors: Robert I. Lehrer, Sylvia L. Harwig, deceased, Chengquan Zhao, In-Hee Lee
-
Patent number: RE38828Abstract: The present invention provides a new class of broad-spectrum antimicrobial peptides effective against a wide variety of microbes, including bacteria, viruses, retroviruses, fungi, yeast and protozoa.Type: GrantFiled: September 24, 2002Date of Patent: October 11, 2005Assignee: IntraBiotics Pharmaceuticals, Inc.Inventors: Robert I. Lehrer, Sylvia S. L. Harwig, Conway C. Chang, Chee L. Gu